Synovium News and Research

RSS

Researchers identify new clues on tissue damage in rheumatoid arthritis and lupus

Research supported by the Accelerating Medicines Partnership on Rheumatoid Arthritis and Systemic Lupus Erythematosus provides new insights into tissue damage for these autoimmune conditions.

19 Jun 2019

New TSPO-targeted PET imaging more fully evaluates extent of rheumatoid arthritis

A new positron emission tomography imaging method more fully evaluates the extent of rheumatoid arthritis by targeting translocator protein expression in the synovium (joint lining tissue).

10 Jul 2018

Studies provide insight into molecular changes prior to onset of arthritis

The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR 2018) provide insight into molecular changes prior to the onset of arthritis which could inform future novel diagnostics and early therapeutic interventions.

18 Jun 2018

Researchers uncover the cause of rheumatoid arthritis

A team of researchers have identified the cellular network involved in initiating and maintaining chronic inflammation in rheumatoid arthritis.

30 May 2018

Phase III clinical study of regenerative therapy for treating damaged cartilage has started

A group of researchers at Osaka University developed a synthetic tissue using synovium-derived mesenchymal stem cells (MSCs) for treating damaged cartilage, which had previously been incurable and had no effective therapies.

4 Jan 2018

Newly developed tool to analyze synovial tissue may lead to better rheumatoid arthritis therapies

A newly developed tool to analyze the cellular and molecular profiles of synovial tissue and peripheral blood may help unlock clues about rheumatoid arthritis and lead to better therapies, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

Partnership between CASIS and NCATS brings Organs-on-Chips research to orbiting laboratory

Models of human disease are beneficial for medical research, but have limitations in predicting the way a drug will behave within the human body using data from non-human models because of inherent differences between species.

21 Jun 2017

Research reveals key role of fibroblasts in development of rheumatoid arthritis

A study led by researchers at the University of Birmingham reveals the key role of different types of fibroblast cells in the development of rheumatoid arthritis (RA), opening up a new avenue for research into treatment of the disease.

23 Nov 2016

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Researchers develop novel technology for chronic arthritis

Joint inflammation (arthritis) is a common problem in medical practice and can be due to a variety of causes. Many types of inflammatory disorders affecting the joints belong to the diverse group of rheumatic diseases.

6 Nov 2015

Immune system protein has potential to prevent onset of aggressive form of rheumatoid arthritis

Scientists have discovered what they believe has the potential to prevent the onset of an aggressive and hard-to-treat form of rheumatoid arthritis - a condition that affects 700,000 adults in the UK.

7 Oct 2015

BRI researchers use tetramer technology to find T cells that drive rheumatoid arthritis

Researchers at Benaroya Research Institute at Virginia Mason used cutting-edge tetramer technology developed at BRI to find the T cells that drive rheumatoid arthritis (RA). "By using tetramer technology, we were able to examine whether T cells in people with rheumatoid arthritis were increased in number or were unique in other ways," says BRI Associate Director Jane Buckner, MD, who led the study with BRI Tetramer Core Laboratory Manager Eddie James, PhD.

12 Jun 2014

Novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis

A novel targeted drug shows promise in treating patients with advanced pigmented villonodular synovitis (PVNS), a rare neoplastic joint disorder, according to new phase I data from Memorial Sloan Kettering Cancer Center and other institutions highlighted to media today in advance of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will take place from May 30 to June 3 in Chicago.

15 May 2014

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Sanofi, Regeneron enroll patients in two sarilumab Phase 3 trials for treatment of RA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered by subcutaneous injection every other week, have enrolled their first patients.

15 May 2013

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

Lung changes in association with ACPA status are a primary manifestation of RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA).

8 Jun 2012

Regulatory T cell diversity provides cumulative protective effect against RA

Untangling the root cause of rheumatoid arthritis has been a difficult task for immunologists, as decades of research has pointed to multiple culprits in our immune system, with contradictory lines of evidence. Now, researchers at The Wistar Institute announce that it takes a diverse array of regulatory T cells (a specialized subset of white blood cells) to prevent the immune system from generating the tissue-specific inflammation that is a hallmark of the disease. Regulatory T cell diversity, the researchers say, provides a cumulative protective effect against rheumatoid arthritis. When that diversity is not present, it allows the immune system to attack joints.

9 May 2012

A rare forum on stem cell biology, engineering and clinical translation

On March 23, during the 41st Annual Meeting & Exhibition of the American Association for Dental Research (AADR), held in conjunction with the 36th Annual Meeting of the Canadian Association for Dental Research, a symposium titled "TMJ: Stem Cell Biology and Engineering toward Clinical Translation" will provide a rare forum for multidisciplinary discussion of the biology, engineering and clinical translation of fundamental discoveries towards novel clinical therapy.

22 Mar 2012

Dual-energy CT has potential to allow non-invasive diagnosis of gout, say radiologists

The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease, according to radiologists at the University of British Columbia, Vancouver General Hospital, in Vancouver, BC.

30 Apr 2011